WuXi Biologics (HKEX: 2269) Announced Sunday August 23, 2026 an Agreement to Sell Its 51.1% Stake in Bestchrom, a Shanghai-Based Supplier of Chromatography Resins and Columns Used Across Peptide and Biologic Manufacturing, to an Undisclosed Independent Third Party; The Divestment Continues WuXi's Strategic Portfolio Pruning Following the January 2025 Sale of Its US Manufacturing Operations to Altaris Capital and the December 2024 Sale of Its Vaccine Manufacturing Business, Repositioning the Chinese CDMO Around Its Core Antibody, Antibody-Drug Conjugate, and Recombinant Protein Contract Manufacturing Services; Bestchrom's Chromatography Resins Are Used Across Peptide API Downstream Purification and Are Part of the Broader Peptide-CDMO Supply Chain
WuXi Biologics (HKEX: 2269) announced Sunday August 23, 2026 an agreement to sell its 51.1% stake in Bestchrom, a Shanghai-based supplier of chromatography resins and columns used across peptide and biologic manufacturing, to an undisclosed independent third party. Financial terms of the transaction were not publicly disclosed. Bestchrom's chromatography resins and columns are used across peptide active pharmaceutical ingredient (API) downstream purification (removing impurities from crude peptide product after synthesis) and are part of the broader peptide-CDMO supply chain that supports the GLP-1 and rare-disease peptide manufacturing scale-up. The divestment continues WuXi's strategic portfolio pruning: the company sold its US manufacturing operations to Altaris Capital in January 2025 following the BIOSECURE Act pressures on Chinese biotech companies serving US customers, and sold its vaccine manufacturing business in December 2024. The Bestchrom divestment repositions WuXi around its core antibody, antibody-drug conjugate, and recombinant protein contract manufacturing services. For the broader peptide manufacturing landscape, the Bestchrom transaction adds another data point to the CDMO consolidation and specialization trend that also includes Samsung Biologics' pending $1.8 billion acquisition of PolyPeptide Group (prospectus expected end of August), the Gland Pharma / Neuland Laboratories sterile API partnership in Visakhapatnam, and ongoing capacity build-outs at Bachem, CordenPharma, and AmbioPharm.